Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 7/20 | 0.41 |
| ▸ | PDE1A | P54750 | 6/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PDE9A | O76083 | 6/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 2/20 | 0.35 |
| ▸ | PDE8A | O60658 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876138 | 0.93 | GRM1 (0.45) | GRM1PDE1BPDE1CPDE1APDE9A | |
| SCHEMBL14790932 | 0.86 | GRM1 (0.38) | GRM1PDE1BPDE1CPDE1APIK3CA | |
| SCHEMBL61885 | 0.83 | PLK4 (0.45) | GRM1PDE1BPDE1CPDE1APIK3CA | |
| SCHEMBL60962 | 0.82 | GRM1 (0.46) | GRM1PDE1BPDE1CPDE1APIK3CA | |
| SCHEMBL14790941 | 0.81 | MERTK (0.46) | GRM1PDE1BPDE1CPDE1APIK3CA | |
| SCHEMBL25876262 | 0.80 | PDE1B (0.40) | GRM1PDE1BPDE1CPDE1APDE9A | |
| SCHEMBL29819928 | 0.80 | MERTK (0.41) | JAK2PDE7AMERTK | |
| SCHEMBL27156375 | 0.80 | MERTK (0.41) | JAK2PDE7AMERTK | |
| SCHEMBL27156379 | 0.80 | MERTK (0.41) | JAK2PDE7AMERTK | |
| SCHEMBL27156479 | 0.80 | MERTK (0.41) | JAK2PDE7AMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | GRM1 3743/4885PDE1B 1866/4885PDE1C 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.